Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Summit Therapeu ADR (SMMT)

Summit Therapeu ADR (SMMT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 621,297
  • Shares Outstanding, K 97,382
  • Annual Sales, $ 860 K
  • Annual Income, $ -52,700 K
  • 60-Month Beta 0.65
  • Price/Sales 31.33
  • Price/Cash Flow N/A
  • Price/Book 5.99
Trade SMMT with:

Options Overview

Details
  • Implied Volatility 93.79%
  • Historical Volatility 59.65%
  • IV Percentile 10%
  • IV Rank 15.97%
  • IV High 536.79% on 09/23/20
  • IV Low 9.57% on 04/19/21
  • Put/Call Vol Ratio 0.77
  • Today's Volume 23
  • Volume Avg (30-Day) 57
  • Put/Call OI Ratio 5.69
  • Today's Open Interest 87
  • Open Int (30-Day) 736

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.29
  • Number of Estimates 1
  • High Estimate -0.29
  • Low Estimate -0.29
  • Prior Year -0.25
  • Growth Rate Est. (year over year) -16.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.21 +2.74%
on 09/13/21
8.39 -23.91%
on 08/30/21
-0.85 (-11.76%)
since 08/17/21
3-Month
6.21 +2.74%
on 09/13/21
8.39 -23.91%
on 08/30/21
-0.29 (-4.35%)
since 06/17/21
52-Week
3.14 +103.18%
on 09/21/20
12.30 -48.13%
on 02/08/21
+3.04 (+91.02%)
since 09/17/20

Most Recent Stories

More News
Korean safety glove manufacturer, Summit Corporation, obtains overseas certification

SEONGNAM-SI, , /PRNewswire/ -- Summit Corporation, a Korean safety glove manufacturer, announced that Summit Corporation acquired EN certification for 3 of leather safety gloves and will accelerate overseas...

SMMT : 6.38 (-1.69%)
Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2021

Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on its operational progress for the second quarter and six months ended...

SMMT : 6.38 (-1.69%)
Summit Therapeutics Provides Update on Ri-CoDIFy Trials

Based on a thorough review of the design and enrollment status of two ongoing blinded Phase III Ri-CoDIFy trials, Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that it will combine its two blinded...

SMMT : 6.38 (-1.69%)
Acurx Pharmaceuticals Joins the Antimicrobials Working Group

/PRNewswire/ -- The Antimicrobials Working Group (AWG) announced today the addition of Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) (Acurx) to its coalition of companies with the mission to combat drug...

CDTX : 2.13 (+1.91%)
ITRM : 0.6256 (+3.75%)
NBRV : 1.1500 (unch)
PRTK : 4.80 (-2.64%)
SCYX : 6.07 (+2.71%)
SMMT : 6.38 (-1.69%)
ACXP : 4.58 (-10.37%)
Summit Therapeutics Presents Breakthrough Research Data from Phase II Studies, including Evidence Validating Microbiome Preservation, for its Investigational Drug Ridinilazole

Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit" or the "Company") is today displaying three preeminent ePosters at the prestigious 31st European Congress of Clinical Microbiology & Infectious Diseases...

SMMT : 6.38 (-1.69%)
Summit Therapeutics to Present Breakthrough Research Updates at the 31st Annual ECCMID Conference, including a Top-Rated ePoster

Summit Therapeutics Inc. (NASDAQ: SMMT) (the "Company") today announced that members of our scientific team will present breakthrough research updates at the 31 European Congress of Clinical Microbiology...

SMMT : 6.38 (-1.69%)
Crestone Joins Antimicrobials Working Group

/PRNewswire/ -- The Antimicrobials Working Group (AWG) announced today the addition of Crestone, Inc. (Crestone) to its coalition of companies with the mission to combat drug resistant infections and...

CDTX : 2.13 (+1.91%)
ITRM : 0.6256 (+3.75%)
NBRV : 1.1500 (unch)
PRTK : 4.80 (-2.64%)
SCYX : 6.07 (+2.71%)
SMMT : 6.38 (-1.69%)
Summit Therapeutics set to join Russell 3000(R) Index

Summit Therapeutics Inc. (NASDAQ: SMMT) is set to join the broad-market Russell 3000(R) Index at the conclusion of the 2021 Russell indexes annual reconstitution, effective after the US markets open on...

SMMT : 6.38 (-1.69%)
Summit Therapeutics' Upcoming Annual Shareholders' Meeting

Summit Therapeutics Inc. (NASDAQ: SMMT) invites our shareholders and other interested parties to attend our Company's Annual Shareholders' Meeting, which will be held virtually on Wednesday, June 16, 2021,...

SMMT : 6.38 (-1.69%)
Summit Therapeutics PLC (SMMT) Moves 17.4% Higher: Will This Strength Last?

Summit Therapeutics PLC (SMMT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price...

SMMT : 6.38 (-1.69%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Average short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Summit Therapeutics PLC is engaged in the discovery and development of drug to treat the fatal muscle wasting disease Duchenne Muscular Dystrophy and infections caused by the bacteria C. difficile. Summit Therapeutics PLC is headquartered in Abingdon, the United Kingdom.

See More

Key Turning Points

3rd Resistance Point 7.10
2nd Resistance Point 6.92
1st Resistance Point 6.65
Last Price 6.38
1st Support Level 6.20
2nd Support Level 6.02
3rd Support Level 5.75

See More

52-Week High 12.30
Fibonacci 61.8% 8.80
Fibonacci 50% 7.72
Fibonacci 38.2% 6.64
Last Price 6.38
52-Week Low 3.14

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar